Lumexa Imaging Holdings Inc

Lumexa Imaging Holdings Inc(LMRI)股票分析

$11.660

+0.824 (+7.07%)收盘时

Loading chart…
最高
11.680
开盘
10.890
成交量加权均价
11.37
成交量
650.39K
市值
—
最低
10.770
成交额
7.39M
企业价值/息税折旧摊销前利润(TTM)
20.86

Lumexa Imaging Holdings, Inc. is a national provider of diagnostic imaging services. The Company offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The Company and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems.

AI 分析 of Lumexa Imaging Holdings Inc (LMRI)

买入

Lumexa Imaging Holdings, Inc. is a good buy right now due to its recent revenue growth of 5.1% year-over-year in Q2, alongside a positive earnings surprise of 233.33% with EPS reported at $0.10 against an estimate of $0.03. The stock's current price of $11.66 is significantly below the analyst price targets of $18, indicating a potential upside of 54.3%. However, the company has a high debt-to-equity ratio of 144.68%, which poses a risk to its financial stability.

估值指标

Lumexa Imaging Holdings Inc(LMRI)当前预期市盈率为 0.00,5 年平均预期市盈率为 0.00。

预期市盈率

严重低估
5 年均值 P/E
0.00
当前P/E
0.00
高估
0.00
低估
0.00

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
35.26
当前EV/EBITDA
20.86
高估
59.52
低估
11.01

预期市销率

合理
5 年均值 P/S
0.90
当前P/S
0.93
高估
1.20
低估
0.60

持有 LMRI 的大户

S

Seven Grand Managers LLC

+ 持有LMRI

-3.98%

3个月收益率

事件时间线

2026-08-12 (ET)

17:00:00

Lumexa Imaging Reports Q2 Revenue of $264.16M

17:00:00

Company Adjusts FY26 Revenue Outlook to $1.05B-$1.1B

2026-06-02 (ET)

07:30:00

Lumexa Imaging Forms Strategic Joint Venture with Hospital for Special Surgery

2026-04-20 (ET)

07:10:00

Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer

2026-03-26 (ET)

09:40:00

Lumexa Imaging Holdings Inc Trading Halted Due to Volatility

资讯

LMRI 常见问题 —— 由 Alphio AI 解答

Lumexa Imaging Holdings, Inc. is a national provider of diagnostic imaging services. The Company offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The Company and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems. It operates in the Healthcare sector.

Lumexa Imaging Holdings, Inc. is a good buy right now due to its recent revenue growth of 5.1% year-over-year in Q2, alongside a positive earnings surprise of 233.33% with EPS reported at $0.10 against an estimate of $0.03. The stock's current price of $11.66 is significantly below the analyst price targets of $18, indicating a potential upside of 54.3%. However, the company has a high debt-to-equity ratio of 144.68%, which poses a risk to its financial stability.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易